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Cystic fibrosis transmembrane conductance
regulator (CFTR) is a cAMP-regulated chloride
channel localized at apical cell membranes and
exists in macromolecular complexes with
a variety of signaling and transporter mole-
cules. Here, we report that the multidrug resis-
tance protein 4 (MRP4), a cAMP transporter,
functionally and physically associates with
CFTR. Adenosine-stimulated CFTR-mediated
chloride currents are potentiated by MRP4 inhi-
bition, and this potentiation is directly coupled
to attenuated cAMP efflux through the apical
cAMP transporter. CFTR single-channel re-
cordings and FRET-based intracellular cAMP
dynamics suggest that a compartmentalized
coupling of cAMP transporter and CFTR occurs
via the PDZ scaffolding protein, PDZK1, form-
ing a macromolecular complex at apical sur-
faces of gut epithelia. Disrupting this complex
abrogates the functional coupling of cAMP
transporter activity to CFTR function. Mrp4
knockout mice are more prone to CFTR-medi-
ated secretory diarrhea.Our findings have impor-
tant implications for disorders such as inflam-
matory bowel disease and secretory diarrhea.
INTRODUCTION
The cyclic nucleotides (e.g., cAMP) are important second
messengers involved in the cellular responses to a wide
variety of signals in every living cell. In epithelial cells lining940 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.the gut, kidney, and lung, cAMP also plays key roles in the
extracellular regulation of fluid homeostasis (Jackson and
Raghvendra, 2004). Tight regulation of intracellular cAMP
levels is critical, because excessive cAMP production
within cells leads to overstimulation of certain secretory
events, dysregulation of cell function, or even cell toxicity.
Increased intracellular cAMP is restored to basal levels via
hydrolysis into 50-AMP by phosphodiesterases (PDEs)
(Jackson and Raghvendra, 2004). Recently, the molecular
identity of a cAMP efflux transporter has been discovered.
MRP4 (ABCC4) is a member of the ATP-binding cassette
(ABC) transporter superfamily, whose gene products are
capable of transporting substrates from the inner mem-
brane leaflet to the outer membrane leaflet (Dean et al.,
2001). MRP4 has been shown to function as a high-affinity
efflux pump for cAMP (Chen et al., 2001; van Aubel et al.,
2002; Wielinga et al., 2003), is expressed in epithelial cells
lining lung, kidney, intestine, etc., and is localized on both
the apical membranes (van Aubel et al., 2002) and basolat-
eral membranes (Lai and Tan, 2002) of polarized cells.
The concept of spatially restricted and tightly modu-
lated compartmentalization of cAMP signaling events
was formulated over 20 years ago (reviewed in Steinberg
and Brunton, 2001; Cooper, 2005). It is well documented
that cAMP signaling specificity relies substantially on
the organization of macromolecular signaling complexes
that effectively assemble multiple proteins (from receptors
to targets) into three-dimensional arrays at subcellular
locations, and that proximity of receptors to their ultimate
targets guarantees response velocity and signaling spec-
ificity (Davare et al., 2001; Huang et al., 2001; Naren et al.,
2003; Li et al., 2005). The assembly of this signaling com-
plex ensures specific and rapid signaling from the recep-
tor to the channel. Stimulation of b2 adrenergic receptors
(b2ARs) in airway epithelial cells also activates chloride
transport mediated by cystic fibrosis transmembrane
conductance regulator (CFTR), the product of the gene
mutated in patients with cystic fibrosis (Li and Naren,
2005). Regulation of the CFTR Cl channel is accomplished
through activation of this apical surface receptor that cou-
ples to adenylate cyclase (AC) and raises cellular cAMP.
Huang and colleagues reported that signaling elements
compartmentalized in apical compartments that activate
CFTR in polarized lung epithelial cells (Huang et al., 2001).
They observed that maximal stimulation of CFTR-mediated
Cl secretion by adenosine, a ligand for A2b adenosine re-
ceptors (A2bARs) that couple to membrane-bound AC, was
accompanied by no measurable change in total cellular
cAMP, signifying highly localized regulation of CFTR by
A2bARs in the apical cell membrane (Huang et al., 2001).
The functional significance of the macromolecular
complex containing CFTR and its interacting partners in
subcellular compartments was reconfirmed (Li et al.,
2005). Most recently, we demonstrated that a type 2 lyso-
phosphatidic acid (LPA) receptor forms a macromolecular
complex with CFTR, a process mediated through a PDZ
scaffolding protein (NHERF2) at the apical surfaces of
gut epithelial cells (Li et al., 2005). The assembly of this
multiprotein complex forms the basis for the functional
coupling between LPA signaling and CFTR-mediated
chloride transport. In the present study, we observed a pre-
viously unidentified functional coupling of a cAMP efflux
transporter (MRP4) to CFTR activity that is physically me-
diated through PDZK1/CAP70 scaffolding protein (Wang
et al., 2000) in a spatially segregated microdomain; this
interaction has important implications for diseases such
as inflammatory bowel disease and secretory diarrhea.
RESULTS
Inhibition of a cAMP Transporter, MRP4,
Potentiates the Function of the Colocalized
CFTR Cl Channel at the Apical Surface of Gut
Epithelial Cells
CFTR is localized at the apical membrane of epithelial cells
lining the gut (Li and Naren, 2005). The functional activity
of this Cl channel is regulated by PKA after a rise in the
local concentration of cAMP. We hypothesized that inhibi-
tion of the plasma membrane cAMP efflux transporter
MRP4 would enhance the cAMP signal and thus magnify
CFTR function. In this study, gut epithelial cells were
permeabilized at the basolateral surface with a-toxin de-
rived from Staphylococcus aureus; the cells were then
pretreated with MK571, a potent MRP4 inhibitor (Reid
et al., 2003). a-toxin forms pores that are permeable to
molecules < 5000 Da, therefore effectively removing the
basolateral membrane as a barrier to cAMP without af-
fecting the functional integrity of the apical membrane
(Reddy and Quinton, 1996). The cell membrane-imper-
meable agonist (cAMP) was added to the permeabilized
surface of polarized gut epithelial cell monolayers to elicit
CFTR-mediated short-circuit currents (Isc). In basolateral-
permeabilized cells pretreated with MK571, a low dose of
cAMP (10 mM) elicited a near-maximal CFTR-mediated Isc,Cwhich was not boosted further by a higher dose of cAMP
(50 mM) (Figure 1A, top). Whereas in untreated (or vehicle-
treated) cells, 10 mM cAMP induced only a very small Isc
response (only 30%–40% magnitude of the MK571-
treated cells), the currents can be further increased to
a maximal level by higher dose of cAMP (50 mM) (Figure 1A,
bottom). However, at a dose of 20 mM cAMP, maximal
CFTR-dependent Isc responses were observed both in
the presence and absence of MK571 (Figure 1B). The Isc
potentiated by MK571 in basolateral-permeabilized gut
epithelial cells were inhibited by various CFTR inhibitors
(glybenclamide, as in Figure 1A; a CFTR-specific inhibitor,
CFTRinh-172, as in Figure S1A in Supplemental Data avail-
able with this article online). Experiments were also per-
formed to demonstrate that cAMP did not activate CFTR
in nonpermeabilized cells when added at either apical or
basolateral surfaces (Figure S2A, bottom). Also, in cells
permeabilized at the basolateral side, cAMP did not
activate CFTR from the apical surface (Figure S2A, top).
We consistently observed that, in MK571-pretreated
cells, the cAMP-activated state of the CFTR Cl channel
is sustained for a relatively longer period of time compared
to untreated cells, i.e., the deactivation of the channel was
relatively slower in the presence of MK571 (Figures 1A,
1B, and S1A). This potentiation (enhancement) of CFTR
function in response to exogenous cAMP by the MRP4
inhibitor (MK571) raises the possibility that attenuated or
blocked, MRP4-mediated, apical cAMP efflux by MK571
may help accumulate higher levels of the second messen-
ger in close proximity to the CFTR Cl channel, thus
resulting in increased CFTR Cl currents, as opposed to
what is seen with the untreated control.
Using an MRP4-specific antibody, we detected MRP4
expression by immunoblotting in the crude membranes
prepared from gut epithelial cells (HT29-CL19A and T84
cells) (Figure 1C). Immunoreactivity for MRP4 was not
observed in the cytosol (Figure 1C). Immunofluorescent
confocal microscopy demonstrated that MRP4 is local-
ized to both the apical and basolateral membranes of
HT29-CL19A cells (Figure 1D, left), with a higher abun-
dance on the apical plasma membrane, where it colocal-
izes partially with CFTR (Figure 1D, right).
cAMP Transporter Function at the Apical
Plasma Membrane of Gut Epithelial Cells
Is Inhibited by MK571
Given that MRP4 is localized in part at the apical mem-
branes of epithelial cells, the unidirectional transport
of etheno-cAMP (a fluorescent analog of cAMP) and
[3H]cAMP across the apical membranes of basolateral-
permeabilized polarized gut epithelial cells was moni-
tored. Etheno-cAMP, like cAMP, is cell impermeant and
induced CFTR-mediated Cl currents in basolaterally
permeabilized epithelial cells only (Figure S3A, bottom).
As MK571 itself has significant autofluorescence when
excited at the same wavelength as etheno-cAMP
(ex315 nm/em420 nm), we used an MRP4 substrate,
9-(2-phosphonyl methoxyethyl) adenine (PMEA), whichell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc. 941
Figure 1. The MRP4 Inhibitor MK571 Po-
tentiates CFTR-Mediated Short-Circuit
Currents
(A and B) Representative traces of CFTR-medi-
ated short-circuit currents (Isc) in response
to cAMP in basolateral-permeabilized HT29-
CL19A cells. Basolateral membranes of the po-
larized cells were permeabilized with 100 mg/ml
a-toxin for 30 min. Cells were pretreated with
20 mM MK571 on both sides before cAMP
was added to the basolateral side. A CFTR
inhibitor, glybenclamide, was added to the
apical side at the end of the experiment.
(C) MRP4 expression in crude plasma mem-
brane prepared from colonic epithelial cells
(HT29-CL19A cells and T84 cells).
(D) Localization of MRP4 and CFTR in polar-
ized HT29-CL19A cells by confocal fluores-
cence microscopy. Top, x-z axis images; bot-
tom, x-y axis images. AP, apical membrane;
BL, basolateral membrane.is a stable, monophosphorylated nucleotide analog
(Schuetz et al., 1999), to compete with etheno-cAMP for
MRP4-mediated efflux across the apical membrane of po-
larized epithelial cells. As illustrated in Figure S3B, PMEA
significantly decreased etheno-cAMP transport across
the apical membrane of HT29-CL19A cells. The inhibitory
effect of PMEA on etheno-cAMP efflux demonstrated942 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.a dose dependence (Figure S3B). Likewise, both MK571
and PMEA dose-dependently decreased the unidirec-
tional transport of [3H]cAMP from the basolateral chamber
into the apical chamber through the apical membrane
MRP4 transporter in HT29-CL19A cells (Figures 2A and
2B). These data clearly show that competitive interactions
with an MRP4 inhibitor (MK571) or substrate (PMEA)Figure 2. cAMP Transport across the Apical Plasma Membrane Is Inhibited by the MRP4 Inhibitor and Substrate
(A and B) Unidirectional transport of [3H]cAMP by the apical MRP4 in basolateral-permeabilized HT29-CL19A cells pretreated with (A) the MRP4
inhibitor MK571 or (B) the MRP4 substrate PMEA. A.U. = arbitrary units. Data represent the mean ± SEM (n = 4).
Figure 3. MRP4 Inhibition Potentiates
CFTR-Mediated Cl Currents in a Com-
partmentalized Manner
(A) CFTR-mediated short-circuit currents (Isc)
in response to adenosine (ADO) and forskolin
(FSK) in MK571-pretreated HT29-CL19A cells
(bottom) or vehicle (DMSO)-treated cells (top).
ADO, FSK, and a CFTR inhibitor, DPC, were
added to the apical side.
(B) CFTR-mediated Isc in response to ADO in
MRP4 siRNA-transfected HT29-CL19A cells
(bottom) or control siRNA-transfected cells
(top). A CFTR-specific inhibitor, CFTRinh-172,
was added to the apical side.
(C) The protein levels of MRP4, CFTR, and
PDZK1 in the cells from (B) were assessed by
western blot with corresponding antibodies
as described in Supplemental Experimental
Procedures.
(D) Cell-attached single-channel recordings of
CFTR currents in vehicle-treated (circle) or
MK571-pretreated (square) HT29-CL19A cells
in response to ADO. NPo: open-state probabil-
ity of the channel. Numbers in parentheses
indicate the number of patches for each condi-
tion. Error bars show SEM.
(E) Dose-dependence curve of CFTR NPo at
different concentrations of MK571 when cells
were activated by 1.5 mM ADO in HT29-
CL19A cells. Data represent the mean ± SEM
(n = 4–6).reduce cAMP efflux across the intact apical MRP4 trans-
porter when the basolateral membrane barrier to cAMP
is removed in polarized epithelial cells.
Inhibition of cAMP Transporter Activity
Potentiates CFTR Function in a
Compartmentalized Fashion
cAMP-elevating ligand adenosine (ADO) has been
reported to stimulate CFTR-mediated Cl currents in
a compartmentalized manner at the apical cell membrane
of polarized epithelial cells (Huang et al., 2001). ADO is
produced at almost 1 mM in unstressed tissue, where-
as in inflamed or ischemic tissues it can be as high as
100 mM (Hasko and Cronstein, 2004). Under conditions
of inflammation (e.g., inflammatory bowel disease), ADO
is generated at sites of tissue stress and injury and se-
creted into the gut, which would eventually activate
CFTR (by acting on certain ARs and causing increased
cAMP production [see Li et al., 2005]) and lead to in-
creased chloride and fluid secretion into the gut lumen
(Barrett and Keely, 2000). Because inhibition of MRP4 byCMK571 reduced the cAMP efflux via apical MRP4 trans-
porter (Figure 2A), and also potentiated CFTR Cl channel
function in response to exogenous cAMP stimulation in
basolateral-permeabilized epithelial cells (Figures 1A and
S1A), we sought to monitor the effect of MK571 on
CFTR-mediated Isc across intact (nonpermeabilized),
polarized gut epithelial cell monolayers in response to
ADO. MK571 potentiated CFTR channel function in re-
sponse to ADO stimulation, and the potentiating effect
of MK571 on CFTR-mediated Cl currents was more
prominent when CFTR was activated with a lower concen-
tration of ADO (at 3 mM ADO, 2-fold Isc for MK571-
treated cells compared to the control; at 50 mM ADO,
1.4-fold Isc for MK571-treated cells compared to the
control) (Figures 3A and Figure S1B). However, MK571
failed to significantly potentiate the channel function
when CFTR was maximally stimulated with a relatively
higher dose of ADO (100 mM) (Figure S2B) or 20 mM forsko-
lin (FSK), the adenylyl cyclase stimulator (Figure 3A),
which causes a global increase of the intracellular cAMP
level (Li et al., 2005). It is worthy to note that MK571 itselfell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc. 943
can induce a very small Isc (3–5 mA/cm2) even in the ab-
sence of ADO stimulation (Figure 3A, bottom).
To test the hypothesis that the potentiating effect of
MK571 on CFTR-mediated Cl currents derives from the
inhibitory effect of MK571 on MRP4 function, we used
MRP4 siRNA oligonucleotides to specifically knock
down the endogenous MRP4 protein amount, then moni-
tored the CFTR-mediated Cl currents in response to
ADO stimulation. MRP4 siRNA significantly enhanced
the ADO-stimulated Isc in HT29-CL19A epithelial cells
compared to control siRNA, with the enhancing effect
occurring at the lower dose (3 mM) of ADO stimulation
(Figure 3B; Figure S1C). When CFTR was stimulated
with a relatively higher dose of ADO (20–100 mM), there
was no difference in CFTR-mediated Isc between control
cells and MRP4 knockdown cells (Figure 3B). The speci-
ficity of MRP4 siRNA was also checked to show that
MRP4 siRNA did not affect the endogenous CFTR or
PDZK1 protein levels (Figure 3C). The Cl currents poten-
tiated by MK571 or MRP4 siRNA in nonpermeabilized gut
epithelial cells were inhibited by a CFTR blocker, DPC
(Figure 3A), and by the CFTR-specific inhibitor, CFTRinh-
172 (Figure 3B; Figures S1B and S1C), suggesting that
the enhanced Isc by MK571 or MRP4 siRNA were medi-
ated through the CFTR Cl channel.
Cell-attached, CFTR single-channel recordings con-
firmed that MK571 leads to compartmentalized accumula-
tion of cAMP at or near the plasma membrane. Varying
concentrations (0–40mM) of ADO were applied in the patch
pipette either to evoke a localized generation of intracellu-
lar cAMP (<20 mM ADO) or to elicit a significantly higher
level (>20 mM ADO) of the second messenger, which might
activate CFTR function submaximally or maximally (Huang
et al., 2001; Li et al., 2005). In gut epithelial cells pretreated
with MK571, the stimulatory effect of ADO on the CFTR
single-channel activity (channel open-state probability,
NPo) was compared with that in the untreated cells (Fig-
ures 3D and S4). The single-channel activity was signifi-
cantly increased at concentrations of 1.5–10 mM ADO in
the presence of MK571 compared to the control (Figures
3D and S4). In contrast, at doses of ADO > 20 mM in the
pipette (leading to a significantly higher increase of intra-
cellular cAMP, which might activate CFTR function sub-
maximally or maximally), MK571 no longer potentiated
channel function. It is to be noted that the NPo of CFTR
Cl channels was significantly higher in MK571-pretreated
cells (NPo = 0.2) compared to untreated cells (NPo = 0),
even in the absence of ADO stimulation (Figure 3D), which
is consistent with the above-described observation that
MK571 itself can induce a very small Isc (3–5 mA/cm2),
even in the absence of ADO stimulation (Figure 3A,
bottom). This suggests that MK571 itself, by inhibiting
MRP4, might restrain a certain amount of localized
cAMP within a microdomain, which is enough to elicit
a certain level of CFTR stimulation. The potentiation of
CFTR function by MK571 also demonstrates a dose de-
pendence; the linear increase range falls within 0–30 mM
of MK571 used when the CFTR channel was stimulated944 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.in a localized pattern by only 1.5 mM ADO (Figure 3E).
MK571 potentiates CFTR activity with concentrations as
low as 10 mM, and it is maximized by 30 mM (Figure 3E).
All of the above-described data suggest that MK571
potentiates CFTR-mediated Cl currents in a locally
restricted manner when CFTR is not maximally activated.
To further characterize the cAMP location after inhibi-
tion of the cAMP transporter, we used a FRET-based
cAMP indicator, CFP-EPAC-YFP (Ponsioen et al., 2004),
to monitor the effect of MK571 on intracellular cAMP sig-
naling and dynamics in response to cAMP-elevating
agents (such as ADO or FSK) in live cells. This highly
sensitive, unimolecular, fluorescent indicator for cAMP
can display significant FRET change, which rapidly dimin-
ishes after a rise in intracellular cAMP and increases again
in response to a fall in cAMP, making it an ideal fluorescent
probe for monitoring cAMP dynamics in living cells (Pon-
sioen et al., 2004). In gut epithelial cells (T84) expressing
the CFP-EPAC-YFP indicator for intracellular cAMP,
FSK, the potent cAMP-raising agent, evoked, on average,
a 29% increase of the CFP/FRET emission ratio (CFP/
FRET emission ratio corresponding to intracellular cAMP
signals; also see Supplemental Experimental Procedures
for details) (Figure S5), which indicates a global increase
of intracellular cAMP. This is consistent with the observa-
tions of Ponsioen et al. (2004). As shown in Figure 4A (top),
MK571 itself also induced a small but substantial increase
of the CFP/FRET emission ratio (8%; indicating in-
creased cAMP level), as observed from Isc measurements
(Figure 3A, bottom) and CFTR single-channel recordings
(Figure 3D). Interestingly, the most prominent increase of
the CFP/FRET emission ratio, after blocking the cAMP
efflux transporter MRP4, occurred at the edge area of
the cells, which indicates a localized (spatially restricted)
cAMP accumulation near the plasma membrane (i.e., sub-
cellular cAMP heterogeneity) (Figure 4A, top).
As expected, ADO elicited a dose-dependent increase
of the CFP/FRET emission ratio. A lower dose of ADO
(2 mM) elicited a smaller increase of the ratio (7%; Fig-
ure 4A, middle, and Figures 4B and 4E) compared to
a higher dose of ADO (100 mM), with a much higher ratio
was observed (24%; Figure 4C, top, and Figures 4D
and 4E). Interestingly, MK571 led to a significant increase
of the cAMP level in addition to the cAMP increase caused
by a lower dose of ADO (2 mM) (from 7% to 17%; Fig-
ure 4A, middle and bottom, Figures 4B and 4E). However,
MK571 failed to execute any significant increase of cAMP
on top of the one caused by a higher dose of ADO (100 mM)
(from 24% to 25%; Figures 4C–4E). These results re-
veal a transition from compartmentalized cAMP elevation
(Figure 4A) to a global increase of intracellular cAMP (Fig-
ure 4C; indicated by the uniform increase of the emission
ratio in the entire cytoplasm), which is similar to the effect
seen with 20 mM FSK (from 28.8% to 29%; Figures 4E
and S5). This finding is consistent with the data from the
above-described functional studies, the Isc measurements
(Figures 1A, 1B, and 3A), and cell-attached single-channel
recordings (Figure 3D). These results imply that the
Figure 4. MRP4 Inhibition Enhances
Intracellular cAMP Signals
(A) The monochrome CFP image showing the
cytosolic distribution of the fluorescent EPAC
probe in T84 cells transfected with CFP-
EPAC-YFP, and representative pseudocolor
images of the CFP/FRET emission ratio before
(time = 0 min) and after the addition of 20 mM
MK571 and/or 2 mM ADO (time = 5 min). The
images in each panel were captured from
the same field of view. The color bar shows
the magnitude of the emission ratio. The scale
bar is 10 mm.
(B) Kinetics of cAMP changes (represented by
the normalized CFP/FRET emission ratio) re-
corded in the cells shown in (A). The arrow indi-
cates the addition of the reagents.
(C) CFP image and representative pseudocol-
ored CFP/FRET ratio images before (time =
0 min) and after the addition of 20 mM MK571
and/or 100 mM ADO (time = 5 min). The probe
was excluded from the nuclear compartments,
although, in these nonconfocal images, a signal
emanating from above and below the nucleus
gives the appearance of a nuclear ratio
change. The scale bar is 10 mm.
(D) Kinetics of cAMP changes (normalized
CFP/FRET emission ratio) recorded in the cells
shown in (C). The arrow indicates the addition
of the reagents.
(E) The summary of all of the experiments per-
formed in the same conditions as in (A)–(D) and
in Figure S5. Data represent the mean ± SEM
(n = 4–6). NS, no significance.increased cAMP accumulation through inhibiting cAMP
efflux (via MRP4 transporter) demonstrates the biggest
magnitude only when it is happening in a compartmental-
ized, spatially restricted microdomain near the plasma
membrane, suggesting a spatial cAMP heterogeneity
within a single cell.
Inhibition of a cAMP Transporter In Vivo
Induces Secretory Diarrhea in Mice
CFTR plays a critical role in cholera toxin (CTX)-induced
intestinal fluid secretion (secretory diarrhea) (Clarke
et al., 1992; Li et al., 2005). Given that MK571 inhibits
MRP4 activity and thus cAMP transport, leading to
CFTR Cl channel activation as demonstrated in the
above-described studies, we therefore hypothesized
that inhibition of MRP4 can induce secretory diarrhea in
mice. To test this hypothesis, the effect of MK571 onCCTX-induced, CFTR-mediated intestinal fluid secretion
was monitored in a closed-loop model of secretory diar-
rhea in wild-type and Mrp4 knockout mice. CTX (0.5 mg)
elicited a fluid accumulation in ligated ileal loops of both
wild-type and Mrp4 knockout mice (Figures 5A and 5B).
MK571 treatment significantly increased the fluid accu-
mulation in the toxin-treated intestinal loops in wild-type
mice (Figure 5A), but failed to do so in Mrp4 knockout
mice (Figure 5B). Interestingly, we observed that the
PBS control loop in Mrp4 knockout mice, compared to
wild-type mice, demonstrated a slightly, also significantly,
higher level of fluid secretion (Figure 5C; 24%, p < 0.05,
n = 10–11). In addition, a CTX-injected loop in Mrp4
knockout mice also demonstrated a significantly higher
level of fluid accumulation compared to the loop in the
wild-type mice (Figure 5C; 27%, p < 0.01, n = 12–13).
The MK571-potentiated, toxin-induced intestinal fluidell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc. 945
Figure 5. MRP4-Deficient Mice Are
More Prone toCFTR-Mediated Secretory
Diarrhea
(A and B) Representative mouse ileal loops 6 hr
after luminal injection with CTX (0.5 mg) with or
without MK571 (20 mM) (picture) in (A) wild-type
mice or (B) Mrp4 knockout mice. The bar
graphs (bottom) show the averaged loop
weight from (A) wild-type mice and (B) Mrp4
knockout mice. The scale bar is 10 mm. Num-
bers in parentheses indicate the repeated
times for each experimental condition. Error
bars show SEM (n = 10–14). NS, no signifi-
cance.
(C) The bar graphs showing the averaged loop
weight injected with PBS with or without CTX
(0.5 mg) from wild-type or Mrp4 knockout
mice. Data represent the mean ± SEM (n =
10–13).
(D) Representative mouse ileal loops 6 hr after
luminal injection with CTX (0.5 mg) + MK571
(20 mM) with or without the CFTR-specific in-
hibitor, CFTRinh-172 (20 mM), in wild-type mice.secretion is mediated through the CFTR Cl channel be-
cause the CFTR-specific inhibitor, CFTRinh-172, signifi-
cantly inhibited fluid secretion (Figure 5D).
Cumulatively, our findings provide clear evidence that,
(i) the potentiating effect on CTX-induced fluid secretion
by MK571 is attributed to the inhibitory effect of MK571
on MRP4 transporter activity; and (ii) MRP4-deficient
mice are more prone to CFTR-mediated secretory diar-
rhea. The latter argument is also supported by the MRP4
siRNA approach described above that is used to specifi-
cally knock down endogenous MRP4, followed by
CFTR-mediated Isc measurement (Figures 3B and S1C).
The data from the intestinal fluid secretion study are con-
sistent with the findings from the Isc study, single-channel
recordings, as well as the FRET-based intracellular cAMP
dynamics described above.
A Macromolecular Complex of the MRP4 C-Tail
and CFTR Is Mediated by PDZK1
Given that we observed a functional coupling between
inhibition of MRP4 transporter activity and potentiation
of CFTR Cl channel function, we next asked if a physical
association between CFTR and MRP4 could be detected
as well. Like CFTR, MRP4 possesses a consensus PDZ
motif at its C terminus (-TALCOOH). Therefore, it is possible
that MRP4 can interact with PDZ proteins via a PDZ motif-
based interaction. We therefore explored the binding
affinity between MRP4 and several PDZ proteins that are
reported to localize to the apical membrane of epithelial
cells (Hung and Sheng, 2002; Li and Naren, 2005). Pull-
down assays demonstrated that MRP4 binds to several
PDZ proteins, and that it binds with the highest affinity to946 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.PDZK1 (Figure 6A). In order to quantify the binding affinity
(EC50) between MRP4 and PDZK1, two purified proteins
were used in a binding kinetics study that demonstrated
that MRP4 interacts with PDZK1 directly, with a binding
constant of EC50 = 3.75 nM (Figure 6B).
We generated a polyclonal antibody against PDZK1
protein and detected expression of PDZK1 in both
HT29-CL19A and T84 gut epithelial cells (Figure 6C).
PDZK1 has been reported to interact with CFTR through
a PDZ-based interaction (Wang et al., 2000). Given that
both MRP4 and CFTR interact with PDZK1, and that these
two transporters are colocalized to the apical membrane
of gut epithelial cells (Figure 1D), we hypothesized that
the interaction between MRP4 and CFTR was likely medi-
ated by PDZK1. To address this, we assembled a macro-
molecular complex of the MRP4 C-tail, PDZK1, and CFTR
in vitro, which is represented schematically in Figure 6D
(top). A macromolecular complex was formed between
the 50 C-terminal amino acids of MRP4, PDZK1, and
CFTR (Figure 6D, bottom). The complex formation in-
creased dose dependently with increasing amounts of
the intermediary protein, PDZK1 (Figure 6D, bottom). We
next immunoprecipitated CFTR from cultured gut epithe-
lial cells that endogenously express all three proteins,
and we demonstrated that both MRP4 and PDZK1 can
be coimmunoprecipitated with CFTR (Figure 6E). These
studies suggest that a macromolecular complex consist-
ing of endogenous MRP4-PDZK1-CFTR is likely present
on the apical surface of gut epithelial cells, and that it
forms the basis for the functional coupling of MRP4 trans-
porter activity to CFTR channel function that we observed
in this study.
Figure 6. A Macromolecular Complex Is
Formed between the MRP4 C-Tail,
PDZK1, and CFTR
(A) MRP4 was pulled down by various GST-
PDZ scaffolding proteins from lysates of
HEK293 cells overexpressing MRP4.
(B) Binding of PDZK1 and 50 amino acids from
the GST-MRP4 C-tail (EC50 = 3.75 nM). The
inset shows a representative immunoblot of
the dose-dependent interaction between His-
PDZK1 and GST-MRP4-C50.
(C) PDZK1 expression in HT29-CL19A and T84
colonic epithelial cells by immunoblotting.
(D) A pictorial representation of the macromo-
lecular complex assay (top; see Supplemental
Experimental Procedures for details). A macro-
molecular complex was detected in vitro with
three purified proteins (GST-MRP4-C50, His-
PDZK1, and Flag-CFTR) in a dose-dependent
manner.
(E) Cell lysates from HT29-CL19A cells were
coimmunoprecipitated with anti-CFTR anti-
body (R1104) and probed for PDZK1 and
MRP4. The MRP4 blot was visualized by using
SuperSignal West Femto Maximum Sensitivity
Substrate (Pierce) because of the weak signal.Disrupting the Macromolecular Complex Inhibits
the Functional Coupling between MRP4 and CFTR
To demonstrate the importance of a macromolecular
complex containing MRP4, PDZK1, and CFTR in the
MK571 potentiation of CFTR function, we disrupted the
complex by using competitive MRP4 PDZ motif peptides
(containing the last 10 amino acids, including the tripep-
tide PDZ motif at the extreme C terminus). We synthe-
sized various peptides, with and without a biotin conju-
gate at the N terminus (MRP4-C10 WT), and mutant
peptides with the alanine substitution point mutation of
the last amino acid within the tripeptide PDZ motif
(MRP4-C10-L1325A) (Figure 7A) and the alanine substitu-
tion mutations of the whole tripeptide PDZ motif (MRP4-
C10-AAA) (Figure S6A). The biotin conjugate facilitated
detection of the peptides with FITC-streptavidin. The
competing efficacy of the peptides was confirmed by
the pull-down in vitro binding studies, which showed
that the synthetic wild-type peptides substantially com-
peted with the GST fusion protein of the 50 C-terminal
amino acids of MRP4 for binding to PDZK1 (Figures 7A
and S6A) compared to the controls. The mutant peptides
demonstrated significantly less efficacy of competition
(Figures 7A and S6A). This clearly shows that the tripep-
tide PDZ motif (-TALCOOH) at the extreme C terminus of
a MRP4 transporter is critical for the physical interaction
between MRP4 and PDZK1. Using a high-efficient pep-
tide delivery system (Chariot system; see Li et al., 2005),
we delivered these peptides into polarized gut epithelial
cells before Isc measurements stimulated by ADO. Our
data clearly demonstrates that the MRP4-specific pep-
tides significantly attenuated the MK571-elicited potenti-
ation of CFTR-mediated currents in gut epithelial cells
(Figure 7B). At the end of the experiment, the epithelialCcells were fixed and immunostained with FITC-streptavi-
din to confirm that the peptide was delivered into the cells
(Figure 7C, right).
To rule out the possibility that the MRP4 peptides might
interfere with other PDZ domain interaction (or these pep-
tides might inhibit PDZK1 interactions with other target
proteins), and to confirm that MRP4 peptide does disrupt
the local macromolecular complex in these peptide-
delivered epithelial cells, we also performed the coimmu-
noprecipitation with PDZK1 antibody. The coimmuno-
precipitated CFTR and MRP4 amounts were checked by
immunoblotting. As the data showed, MRP4 wild-type
peptide significantly reduced the endogenous MRP4 pro-
tein amount that was coimmunoprecipitated with PDZK1
in HT29-CL19A epithelial cells (Figure S6B, right). How-
ever, MRP4 wild-type peptide did not affect the CFTR
amount coimmunoprecipitated with PDZK1 (Figure S6B,
left), which suggests the specificity of the MRP4 peptide.
MRP4-L1325A mutant peptide behaved in a similar
fashion to the biotin control (Figure S6B).
DISCUSSION
Secretory epithelia perform vectorial transport of salt and
water molecules by coordinated actions of the trans-
porters expressed in polarized epithelial membranes,
and CFTR is one of the key membrane proteins regulating
overall fluid movements. Hypo- or hyperfunctioning of
CFTR can cause aberrant membrane transport and may
result in life-threatening diseases, such as cystic fibrosis
or secretory diarrhea (Kunzelmann and Mall, 2002). There-
fore, the fine-tuned regulation of salt and water transport is
essential in epithelial and body homeostasis.ell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc. 947
Figure 7. MRP4 Peptides that Disrupt
MRP4 Interaction with PDZK1 Attenuate
Elevation of CFTRClCurrentsMediated
by MRP4 Inhibition
(A) PDZK1 binding to MRP4 in the presence
of biotin-conjugated MRP4 C-tail peptides
(last 10 amino acids; wild-type and mutant
L1325A). The bar graphs (bottom) show the av-
eraged band density from respective groups.
Data represent the mean ± SEM (n = 3).
(B) Representative short-circuit current (Isc)
traces in response to ADO in HT29-CL19A-
polarized cells. MRP4 peptides (2 mM) were
delivered to the cells before Isc measurement.
Cells in all groups were pretreated with 20 mM
MK571 for 30 min before activation with ADO.
Bar graphs summarize the averaged maximal
Isc after each dose of ADO as a percentage of
the control. Results are presented as mean ±
SEM (n = 3–4 for each group). NS, no signifi-
cance; **p < 0.01; ***p < 0.001 compared with
the control for each ADO dose.
(C) Immunofluorescence micrographs of HT29-
CL19A cells from (B) showing the biotin-conju-
gated MRP4 peptides (green; right) delivered
into the polarized cells. The nucleus was
stained with propidium iodide (red). FITC-
streptavidin was used to detect the biotin con-
jugated with the peptides.
(D) Schematic representation of the compart-
mentalized signaling involved in the spatiotem-
poral coupling of cAMP transporter (MRP4) to
the CFTR Cl channel in the gut epithelia. Refer
to the Discussion for details.Spatiotemporal Coupling of cAMP Transporter
Function and CFTR Cl Channel Activity
In the present study, we found that inhibition of a cAMP
transporter, MRP4, by MK571 potentiated CFTR-mediated
Cl currents. We also observed that potentiation of CFTR
function by MK571 was most prominent when CFTR was
activated by lower concentrations of ADO (<20 mM), but
not with higher doses of agonists (>20 mM). This suggests
that lower doses of ADO may lead to compartmentalized
cAMP accumulation, which is further enhanced by the
reduced or inhibited cAMP efflux through MRP4 by
MK571. This finding is consistent with the previous obser-
vation that cAMP is generated in a compartmentalized
pocket upon stimulation by 2 mM ADO, which is enough
to activate CFTR function in the proximity, and that LPA,
a cAMP-lowering agent, significantly inhibits CFTR func-
tion (Li et al., 2005). Here, the concept of cAMP compart-
mentalization was recapitulated with the treatment of
MK571, which significantly potentiated CFTR function
when it was stimulated by lower doses of ADO. It has
been reported that inhibiting the transport of MRP4 does
not lead to substantial increases of intracellular cyclic nu-
cleotide levels (globally); neither does overexpression of948 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.MRP4 lead to a substantial decrease in intracellular
cAMP levels, even when these levels are high (Wielinga
et al., 2003). This is probably because the inhibition of
MRP4 resulted only in localized fluctuations of cyclic nu-
cleotide levels, but not global levels.
Based on previous findings and the data obtained from
this study, we propose a model depicting the spatiotem-
poral coupling of cAMP transporter to CFTR Cl channel
function in the gut epithelia (Figure 7D). Underneath the
apical plasma membrane, highly localized compartments
exist and contain a series of signaling molecules such as
AR; G protein (Gs); AC; PKA and its anchoring proteins,
AKAPs; CFTR; cAMP transporter (MRP4); and PDZ scaf-
folding proteins (in this case, PDZK1). PDZK1 functions
to physically connect CFTR to MRP4. This macromolecu-
lar signaling complex provides a potential anatomical
basis for the generation and modulation of local cAMP
compartments. When an agonist (in this case, ADO) binds
AR, a series of G protein-mediated reactions leads to the
activation of AC present in the apical membrane. Suffi-
cient cAMP (red spheres; Figure 7D) is locally generated
in a diffusionally restricted apical microdomain (but not
in other cellular compartments). cAMP activates PKA,
which is also anchored to the apical membrane by AKAP
(i.e., ezrin), and phosphorylates the CFTR Cl channel in
the close vicinity, resulting in an increase of Cl currents.
The CFTR-mediated Cl currents can be further increased
(potentiated) through the additional increase of local
cAMP resulting from the reduced or blocked efflux via a
neighboring apical membrane cAMP transporter (MRP4)
in the same subcellular compartment.
In general, it is believed that PDEs provide the sole
means for degrading cAMP in cells and play a vital role
in shaping intracellular gradients of the second messenger
(Cooper, 2005; Jackson and Raghvendra, 2004). Here, we
identified additional means of regulating cAMP levels in
a microdomain underneath the surface membrane, an
efflux path for cAMP via the MRP4 transporter in the close
vicinity of the CFTR-containing signaling complex. The in-
teraction between CFTR and MRP4 provides an additional
layer of mechanism to regulate CFTR function, which is
important in maintaining epithelial and body homeostasis.
Macromolecular Signaling Complex in the Gut
PDZ domains are conserved protein-interaction modules
that are 80–90 amino acids long, fold to form peptide-
binding clefts, and typically mediate interactions with the
carboxyl termini of target proteins that terminate in con-
sensus PDZ-binding sequences (i.e., PDZ motif) (Hung
and Sheng, 2002; Li and Naren, 2005). PDZK1 has been
reported to interact with CFTR, SLC26A3 (downregulated
in adenoma [DRA]), SLC26A6 (putative anion transporter 1
[PAT1]), and the Na+/H exchanger NHE3, the major
transport proteins for intestinal anion secretion and salt
absorption (Lamprecht and Seidler, 2006). Many studies
have reported the association of these PDZ proteins
with a wide variety of ion channels, receptors, trans-
porters, and signaling proteins on the apical surfaces of
cells, suggesting that apical membrane PDZ proteins
could facilitate the formation of multiprotein complexes
clustered within microdomains that modulate trafficking,
transport, and signaling in polarized epithelial cells
(Wang et al., 2000; Lamprecht and Seidler, 2006).
Compartmentalization of signaling complexes contain-
ing CFTR, PDZK1, and MRP4 (Figure 7D) has important
implications. Our present study demonstrates a physically
and functionally interacting macromolecular complex
containing two ABC transporters mediated by a PDZ scaf-
folding protein, which may have significant in vivo physio-
logical or pathophysiological relevance. Under normal
conditions, MRP4 pumps out cAMP, which is in proximity
to CFTR, thus modulating CFTR function stimulated by
cAMP-producing pathways (such as ADO). Under aber-
rant conditions (such as inflammatory bowel disease
with diarrhea or irritable bowel syndrome with constipa-
tion), the expression levels and/or subcellular localization
of CFTR and/or MRP4 may be dysregulated. The ratio of
CFTR to MRP4 may be altered, thereby resulting in ele-
vated or reduced cAMP accumulation in the compartment
and leading to enhanced or attenuated CFTR-mediated
Cl transport, which consequently results in secretoryCdiarrhea in inflammatory bowel disease or constipation
occurring in irritable bowel syndrome. In inflamed colonic
mucosa of mice with inflammatory bowel disease, CFTR
expression was increased 2.5-fold compared to nonin-
flamed samples (Lohi et al., 2002). Elevated CFTR expres-
sion and enhanced cAMP-dependent Cl secretion have
been demonstrated in hyperproliferated mouse intestine
(Umar et al., 2000). In Cftr knockout mice, ileal mucosal
bile acid absorption is increased significantly compared
to wild-type mice (Stelzner et al., 2001). Interestingly,
MRP4 is reported to be an alternative bile acid export
pump (Rius et al., 2003). This suggests a possible upregu-
lation of MRP4 function in the absence of CFTR. Our pres-
ent studies have significant in vivo implications for
diseases such as secretory diarrhea, inflammatory bowel
disease, and irritable bowel syndrome.
EXPERIMENTAL PROCEDURES
Short-Circuit Current Measurements
Polarized colonic epithelial cells (HT29-CL19A and T84) were grown
to confluency on permeable supports before they were mounted in a
Ussing chamber, and short-circuit currents (Isc) were measured as
reported previously (Li et al., 2005). MK571 (5–50 mM) was added to
both the apical and basolateral sides for 30 min before ADO was added
to the apical side. In some experiments, cells were permeabilized at
the basolateral side with 100 mg/ml a-toxin for 30 min at 37C before
the Isc measurement was taken. The CFTR inhibitor DPC (500 mM),
glybenclamide (500 mM), or CFTRinh-172 (2–10 mM) was added onto
the apical side.
[3H]cAMP and Etheno-cAMP Transport Assay across Apical
Cell Membranes
HT29-CL19A and T84 cells were permeabilized at the basolateral side
with a-toxin as described above, and they were incubated with MK571
or PMEA at 37C for 30 min. [3H]cAMP or etheno-cAMP was added
into the basolateral chamber containing 4 mM ATP (Mg salt). For the
[3H]cAMP transport assay, an aliquot of 40 ml apical solution was col-
lected at various time points, and the radioactivity was measured with
a liquid scintillation counter (LS5000TA; Beckman Coulter, Fullerton,
CA). For the etheno-cAMP transport assay, an aliquot of 40 ml apical
solution was collected, and the fluorescence was measured at wave-
length ex315 nm/em420 nm with a fluorescence spectrophotometer
(F-2500; Hitachi, Tokyo, Japan).
Coimmunoprecipitation and Immunoblotting
Cells were harvested and processed for coimmunoprecipitation and
immunoblot as described previously (Li et al., 2005). Cells were solubi-
lized in RIPA buffer for immunoblot alone or in PBS-0.2% Triton X-100
for coimmunoprecipitation, and lysates were spun at 15,000 3 g for
15 min at 4C to pellet insoluble material and processed for coimmu-
noprecipitation and immunoblot as described in detail in Supplemental
Experimental Procedures.
Cell-Attached Single-Channel Recordings
Single-channel recordings were obtained from HT29-CL19A cells as
reported previously (Li et al., 2005). CFTR channels were activated
with adenosine (0–40 mM) included in the pipette as indicated. Sin-
gle-channel currents were continuously recorded for 5 min at a test
potential of +100 mV (referenced to the cell interior) delivered from
the recording electrode and were filtered at 1 kHz and sampled at
2 kHz (Li et al., 2005; details in Supplemental Experimental Proce-
dures).ell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc. 949
FRET Imaging Microscopy and Image Analysis
Cells (expressing CFP-EPAC-YFP) for FRET imaging were seeded in
35 mm glass-bottom dishes (MatTek) and were grown for 24–48 hr
and washed with HBSS before being mounted on an Olympus micros-
copy system for FRET imaging. Images were recorded with a cooled
CCD Hamamatsu ORCA285 camera (Hamamatsu, Japan) mounted
on the Olympus microscope IX51 (U-Plan Fluorite 603 1.25 NA oil-im-
mersion objective), and the system was controlled by SlideBook 4.1
software (Intelligent Imaging Innovations, Denver, CO); ratio and
FRET modules were used to obtain and analyze the images. Excitation
light was provided by a 300W Xenon lamp and was attenuated with
a ND filter with 50% light transmission. Images were captured by using
a JP4 CFP/YFP filter set (Chroma, Brattleboro, VT) including a 430/
25 nm excitation filter, a double dichroic beam splitter, and two emis-
sion filters (470/30 nm for CFP and 535/30 nm for FRET) alternated by
a filter-changer Lambda 10-3 (Sutter Instruments, Novato, CA). Time-
lapse images were acquired with a 43 4 binning mode, a 200–400 ms
exposure time, and 1 min intervals to reduce photobleaching of the flu-
orophores. Acquired fluorescent images were background subtracted,
and multiple regions of interest (ROIs) on the cell periphery were se-
lected for quantitative data analysis (20–30 ROIs per cell, and 4–6
cells per condition were averaged). The emission ratio images (CFP/
FRET) were generated at different time points on a pixel-by-pixel basis
by the SlideBook ratio module as formulated below,
R=
Emission intensity of background-subtracted CFP image
Emission intensity of background-subtracted FRET image
: (1)
The ratio (R) was normalized as Rt/R0, where Rt is the ratio at time
point t and R0 is the ratio at time point 0 (just before the addition of
the first test compound). The cell images are presented in pseudocolor
to highlight the changes in the ratio of CFP/FRET fluorescence intensity.
Macromolecular Complex Assembly
The in vitro complex formation (Li et al., 2005) was performed by mixing
GST-His-S-MRP4-C terminal 50 aa fusion protein (20 mg) with various
amounts of His-S-PDZK1 (0–40 mg) and 0.5 mg purified Flag-tagged
WT-CFTR at 4C for 3 hr (Li et al., 2005; details in Supplemental Exper-
imental Procedures).
MRP4 Peptide In Vitro Competitive Binding
MRP4 peptides (biotin-conjugated wild-type or L1325A mutant pep-
tide, or nonconjugated wild-type or C10-AAA mutant peptide; 2 mM
each) were mixed with His-PDZK1 (1.3 and 6.6 nM) at 22C–24C for
1 hr before GST-MRP4-C50 (immobilized on glutathione beads) was
added; the solution was then mixed for another hour. The beads
were washed, and the protein complex was eluted from the beads,
separated by SDS-PAGE, and immunoblotted with rabbit anti-
PDZK1 polyclonal antibody as described above.
Delivery of MRP4 Peptide into Polarized Epithelial
Cells, followed by Immunocytochemistry
and Coimmunoprecipitation
Delivery of MRP4-specific peptide was performed as reported before
(Li et al., 2005) and is described in detail in Supplemental Experimental
Procedures. After Isc measurement, the cells were fixed and immuno-
stained for the peptides by using FITC-conjugated streptavidin. In
some experiments, after peptide delivery and Isc measurement, cells
in the filters were scraped into RIPA buffer, and coimmunoprecipitation
with rabbit PDZK1 antibody was performed. Endogenous CFTR and
MRP4 protein amounts in the coimmunoprecipitated complex were
checked by immunoblotting with anti-CFTR (R1104 monoclonal) and
anti-MRP4 (M4I-10, rat monoclonal) antibodies as described above.950 Cell 131, 940–951, November 30, 2007 ª2007 Elsevier Inc.MRP4 siRNA to Knock Down MRP4 in Polarized
Epithelial Cells
MRP4 siRNA and Lipofectamine 2000 transfection reagent were
prepared and mixed according to the manufacturer’s instructions.
siRNA-Lipofectamine 2000 complexes were added to HT29-CL19A
cells grown to confluency on transwells and were incubated at 37C
in a CO2 incubator. After 60–72 hr, the transwells were mounted in
a Ussing chamber for Isc measurement in response to ADO stimulation.
After the Ussing chamber study, the transwells were washed with PBS,
and the cells were scraped into RIPA lysis buffer. The protein levels of
MRP4, CFTR, and PDZK1 were assessed by western blot with corre-
sponding antibodies.
Statistical Analysis
Results are presented as mean ± SEM for the indicated number of
experiments. Statistical analysis was performed by using a Student’s
t test and one-way ANOVA. A value of p < 0.05, p < 0.01, or p <
0.001 was considered statistically significant.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and six figures and can be found with this
article online at http://www.cell.org/cgi/content/full/131/5/940/DC1/.
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